Moonlake Immunotherapeutics Stock News

MoonLake Immunotherapeutics said on Monday its experimental drug met all main goals in a late-stage trial involving ​adults with an inflammatory disease who had not previously ‌received biologic medicines.

Phase 3 IZAR-1 trial in bio-naïve patients met all clinical endpoints at Week 16 for 60 mg sonelokimab The primary endpoint of ACR50 was met with a high response of 42.1% for sonelokimab's 60 mg with induction, and significant responses were observed across key secondary endpoints, including ACR20 (66.5%), MDA (41.2%) and PASI90 (61%), supporting the broad multidomain efficacy profile of sonelo...